Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

Stopped Company decision taken in light of demands by certain national health authorities

Conditions

• Obesity
• Diabetes Mellitus Type 2

Interventions

• DRUG: Rimonabant
• DRUG: Placebo (for Rimonabant)
• DRUG: Anti-diabetic monotherapy

Sponsor

Sanofi